Rapid, adaptable and sensitive Cas13-based COVID-19 diagnostics using ADESSO

Beatrice Casati, Joseph Peter Verdi, Alexander Hempelmann, Maximilian Kittel, Andrea Gutierrez Klaebisch, Bianca Meister, Sybille Welker, Sonal Asthana, Salvatore Giorgio, Pavle Boskovic, Ka Hou Man, Meike Schopp, Paul Adrian Ginno, Bernhard Radlwimmer, Charles Erec Stebbins, Thomas Miethke (), Fotini Nina Papavasiliou () and Riccardo Pecori ()
Additional contact information
Beatrice Casati: German Cancer Research Centre (DKFZ)
Joseph Peter Verdi: German Cancer Research Centre (DKFZ)
Alexander Hempelmann: German Cancer Research Centre (DKFZ)
Maximilian Kittel: University of Heidelberg
Andrea Gutierrez Klaebisch: University of Heidelberg
Bianca Meister: University of Heidelberg
Sybille Welker: University of Heidelberg
Sonal Asthana: German Cancer Research Centre (DKFZ)
Salvatore Giorgio: German Cancer Research Centre (DKFZ)
Pavle Boskovic: German Cancer Research Centre (DKFZ)
Ka Hou Man: German Cancer Research Centre (DKFZ)
Meike Schopp: German Cancer Research Centre (DKFZ)
Paul Adrian Ginno: German Cancer Research Centre (DKFZ)
Bernhard Radlwimmer: German Cancer Research Centre (DKFZ)
Charles Erec Stebbins: German Cancer Research Centre (DKFZ)
Thomas Miethke: University of Heidelberg
Fotini Nina Papavasiliou: German Cancer Research Centre (DKFZ)
Riccardo Pecori: German Cancer Research Centre (DKFZ)

Nature Communications, 2022, vol. 13, issue 1, 1-11

Abstract: Abstract During the ongoing COVID-19 pandemic, PCR testing and antigen tests have proven critical for helping to stem the spread of its causative agent, SARS-CoV-2. However, these methods suffer from either general applicability and/or sensitivity. Moreover, the emergence of variant strains creates the need for flexibility to correctly and efficiently diagnose the presence of substrains. To address these needs we developed the diagnostic test ADESSO (Accurate Detection of Evolving SARS-CoV-2 through SHERLOCK (Specific High Sensitivity Enzymatic Reporter UnLOCKing) Optimization) which employs Cas13 to diagnose patients in 1 h without sophisticated equipment. Using an extensive panel of clinical samples, we demonstrate that ADESSO correctly identifies infected individuals at a sensitivity and specificity comparable to RT-qPCR on extracted RNA and higher than antigen tests for unextracted samples. Altogether, ADESSO is a fast, sensitive and cheap method that can be applied in a point of care setting to diagnose COVID-19 and can be quickly adjusted to detect new variants.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-30862-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30862-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-30862-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().